SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons sharp rally is drawing attention after Morgan Stanley named it a top pick, citing AWS growth and AI opportunities. Traders are broadly bullish, though some question whether the move can hold and point to earnings and technical resistance as potential tests.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Goldman Sachs upgraded CoreWeave to Buy while lowering its price target, drawing attention after a sharp selloff in AI infrastructure stocks. Traders debated whether the upgrade and AI demand could support a rebound or whether heavy debt and financing concerns would keep pressure on the shares.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBios expanded FDA approval of ANKTIVA for papillary-only BCG-unresponsive bladder cancer, alongside long-term Phase 3 data showing durable responses and cystectomy avoidance, is driving attention. Traders are frustrated by the share-price drop despite the positive developments, debating a sell-the-news reaction and broader biotech weakness versus unverified claims of short-selling pressure.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Better-than-expected third-quarter results and a substantially more upbeat 2027 earnings outlook are driving CLF attention and a sharp rally. Traders are debating whether the forecast and steel-price tailwinds can overcome debt and execution concerns, while some view the move as vulnerable to profit-taking or short-covering volatility.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Sea shares are drawing attention after a sharp slide and technical breakdown, with traders repeatedly pointing to insider share sales as added selling pressure. Some view the sales as planned and the decline as disconnected from the companys growth, while others worry about management confidence and cite broader Southeast Asian market and oil-related risks.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

Disc Medicine is surging after bitopertin met all primary and secondary endpoints in the Phase 3 APOLLO trial for erythropoietic protoporphyria, strengthening the companys path toward an FDA resubmission. Traders are broadly bullish and debating a possible short squeeze, while some cite dizziness concerns and potential profit-taking.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

CBRS is drawing attention amid a steep post-IPO selloff, with traders pointing to successive insider-share unlocks and a broader AI and semiconductor pullback. Bears cite the companys high valuation, scaling concerns and OpenAI dependence, while bulls argue the decline is overdone and are buying dips.

Almonty Industries, Inc. engages in the mining, processing, and shipment of tungsten concentrates. Its projects include Almonty Korea Tungsten, Panasquiera mine, Gentung, Almonty Korea Moly, Los Santos mine, and Valtreixal. The company was founded on September 28, 2009 and is headquartered in Dillon, MT.

Almonty Industries Inc

Almontys investor-day webcast is driving concern, with traders criticizing CEO Lewis Blacks presentation and questioning whether it signaled an undisclosed problem. Others say the content sounded positive and see no clear negative update, leaving the selloffs cause uncertain.

X-Energy, Inc. engages in the development of advanced small modular nuclear reactors and fuel technology for clean energy generation. Its solutions include Xe-100 and TRISO-X. The company was founded by Kam Ghaffarian and Eben Mulder in 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-Energy Inc

Traders are focused on AEP and X-energy evaluating a potential 960-MW small modular reactor project in Indiana, with Amazon funding development and potentially buying power long termfueling optimism about nuclear power for data centers. The project remains at the evaluation stage, and enthusiasm over the opportunity is tempered by concern about XEs sharp selloff and the long path to commercial deployment.

Dynex Capital, Inc. is an internally managed mortgage real estate investment trust. It engages in the business of investing in mortgage-backed securities. The company was founded on December 18, 1987 and is headquartered in Glen Allen, VA.

Dynex Capital, Inc.

Dynexs Q3 results have focused attention on a sharp book-value decline as wider agency mortgage spreads drove losses, alongside earnings below the dividend payout. Traders are split between buying the dip on managements confidence in liquidity and future spread recovery, and worrying about dividend coverage and further share-price downside.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

LEGN’s New CEO From Novartis Paves Way For Buyout Speculation 

Equity

Legend’s new CEO Ingrid Zhang most recently served as chief commercial officer for Novartis International.


Legend Biotech Appoints Ingrid Zhang As CEO

(RTTNews) - Legend Biotech Corp. (LEGN), a cell therapy company, on Tuesday appointed Ingrid Zhang as Chief Executive Officer, effective September 15...

Legend Biotech (LEGN) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Legend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles Consensus

Legend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles Consensus...

LEGN Stock Plunges 15% After Sudden CEO Exit — But Analyst Reiterates Optimism In Company’s Under-Development Lymphoma Asset 

Legend said on Monday that Ying Huang stepped down as chief executive officer and board member effective July 24. 


Legend Biotech Corporation (LEGN) Price Target Raised to $49 on LB5006 Clinical Progress

Legend Biotech Corporation (LEGN) Price Target Raised to $49 on LB5006 Clinical Progress...

Why Is Legend Biotech Stock Falling Thursday?

Legend Biotech (LEGN) shares drop in premarket trading after pricing a $226M public offering. Get the latest technical levels here.read more...

Legend Biotech, Sleep Number And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

US stock futures up, Nasdaq futures 1% higher. Legend Biotech (LEGN) priced 7.7 million ADSs at $29.35 each, shares down 9% in pre-market trading.read more...

These Analysts Revise Their Forecasts On Legend Biotech After Q1 Results

Legend Biotech (LEGN) reported Q1 losses of 3 cents per share and sales of $305.1 million, missing estimates. Stock rose 1.3% to $28.63. Analysts maintained ratings and adjusted price targets.read...

Legend Biotech Q1 Earnings Call Highlights

Legend Biotech Q1 Earnings Call Highlights...

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Bridgewater, NJ.

Legend Biotech Corp - ADR

Bearish Sentiment

<ul class="summary-bullets"><li>Chairman Frank Zhang said the board picked Ingrid Zhang after a full search to guide Legend through its next phase of growth.</li><li>Legend’s commercial engine is CARVYKTI, a CAR-T cell therapy for multiple myeloma developed and sold with Johnson &amp; Johnson.</li><li>Retail is anticipating a buyout of Legend, with some speculating it would come from one of the company’s partners.</li></ul>Legend Biotech (LEGN) named Ingrid Zhang as chief executive on Tuesday, ending a two-month search that began when former CEO Ying Huang resigned in July and setting the stage to expand its offerings beyond CARVYKTI and paving the way for buyout speculation.The company said that the new CEO appointment is effective immediately. Alan Bash, who ran the company on an interim basis, will return to his job as president of CARVYKTI.Zhang most recently served as chief commercial officer for Novartis International. She also led Novartis’s China business and its innovative-medicines organization and spent earlier years at AstraZeneca, Pfizer, and McKinsey. Chairman Frank Zhang said the board picked her after a full search to guide Legend through its next phase of growth. Zhang said she wants to build on the company’s cell-therapy foundation, push the pipeline, and execute the long-term plan.<h2 class="st-heading-2">JNJ Partnership For CARVYKTI</h2>Legend’s commercial engine is CARVYKTI (ciltacabtagene autoleucel), a CAR-T cell therapy for multiple myeloma developed and sold with Johnson &amp; Johnson. The partners share costs and profits outside Greater China. CARVYKTI is now in 19 markets and about 348 treatment centers. Second-quarter net trade sales were about $657 million, up 50% from a year earlier. Full-year 2025 sales were about $1.9 billion, and first-half 2026 sales were about $1.25 billion. Legend is still trying to move the drug earlier in myeloma, with several studies studying the drug in newly diagnosed patients.<h2 class="st-heading-2">Novartis-Legend Partnership</h2>In November 2023, Legend licensed Novartis exclusive worldwide rights to DLL3-targeted CAR-T therapies, including LB2102, for small-cell lung cancer and related tumors. Novartis paid $100 million up front and could owe up to $1.01 billion in milestones, plus royalties.Legend ran the U.S. early-stage study for LB2102. Novartis is responsible for later development, manufacturing, and sales. Early LB2102 data showed responses in heavily pretreated patients; the program is now in follow-up.Beyond that, Legend is advancing LB1908 in gastric and pancreatic cancers, LB2401 in myeloma, and an in vivo CAR-T program, LB2501, with an investigational new drug filing expected in the second half of 2026.<h2 class="st-heading-2">How Did LEGN Retail Traders React?</h2>On Stocktwits, retail sentiment around LEGN stock shifted from ‘bearish’ to ‘neutral’ over the past 24 hours, while message volume rose from ‘extremely low’ to ‘high’ levels.A Stocktwits user expressed optimism about Novartis buying Legend.<stembedurl>https://stocktwits.com/KY3000/message/664330468</stembedurl>Another user applauded the new CEO appointment, saying it might allow the company to put favorable pressure on its other partner, Johnson. “A blockbuster drug and a very promising pipeline will ultimately reward investors,” they added.<stembedurl>https://stocktwits.com/Stockseeking/message/664324550</stembedurl>A third user opined that the stock is undervalued at current levels.<stembedurl>https://stocktwits.com/mulc/message/664318036</stembedurl><a href="https://stocktwits.com/symbol/LEGN">LEGN stock</a> has fallen 19% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/iova-flags-year-end-data-slate-after-record-amtagvi-quarter-highlights-clear-line-of-sight-to-profitability/cZtnpgQRBcy">IOVA Flags Year-End Data Slate After Record Amtagvi Quarter, Highlights ‘Clear Line Of Sight To Profitability’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Legend Biotech Corporation logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Legend’s new CEO Ingrid Zhang most recently served as chief commercial officer for Novartis International.

LEGN’s New CEO From Novartis Paves Way For Buyout Speculation

Johnson & Johnson

Legend Biotech

Novartis AG

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$18.20
Prev Close	$18.48
Open	$18.70
Dividend Yield	0.00%
50-Day Moving Average	$19.71
Beta	0.55
Avg. Volume	2.22M
PE Ratio	-37.03

52-Week High	$37.50
52-Week Low	$16.24
Market Capitalization	$3.58B
EPS (Annual)	-$1.61
Price to Book	2.91
Revenue Per Employee	$355,731.44

Feed

News

Sentiment

Earnings

Fundamentals

Info

LEGN Fundamentals